Exact Sciences Announces First-Quarter 2024 Results
Exact Sciences Corporation (EXAS)
Last exact sciences corporation earnings: 2/11 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.exactsciences.com/investor-relations/default.aspx
Company Research
Source: Business Wire
First quarter highlightsDelivered total first quarter revenue of $638 million, an increase of 6% on a reported and core revenue basis, including Screening revenue of $475 million and Precision Oncology revenue of $163 millionPublished Cologuard Plus™ test results from pivotal BLUE-C study in The New England Journal of MedicineMaintains full-year 2024 revenue and adjusted EBITDA guidance MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $638 million for the first quarter ended March 31, 2024, compared to $602 million for the same period of 2023.“The Exact Sciences team is off to a strong start again in 2024. Our team delivered more than a million Cologuard® and Oncotype DX® test results to patients and advanced our deep pipeline of life-changing cancer diagnostics,” said Kevin Conroy, chairman and CEO. “As we expand our portfolio globally, our seamles
Show less
Read more
Impact Snapshot
Event Time:
EXAS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EXAS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EXAS alerts
High impacting Exact Sciences Corporation news events
Weekly update
A roundup of the hottest topics
EXAS
News
- Foundation Fighting Blindness Partners with PreventionGenetics and InformedDNA to Advance My Retina Tracker® Genetic Testing Program [Yahoo! Finance]Yahoo! Finance
- Is Climate Change Behind A Mysterious Algal Bloom In Patagonia? [Forbes]Forbes
- Exact Sciences Corporation (NASDAQ:EXAS) First-Quarter Results: Here's What Analysts Are Forecasting For This Year [Yahoo! Finance]Yahoo! Finance
- Exact Sciences First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags [Yahoo! Finance]Yahoo! Finance
- The National Institute for Health and Care Excellence (NICE) Recommends Use of Exact Sciences' Oncotype DX® Test to Help Guide Chemotherapy Decisions for Node-positive Breast Cancer Patients [Yahoo! Finance]Yahoo! Finance
EXAS
Earnings
- 5/8/24 - Miss
EXAS
Sec Filings
- 5/8/24 - Form 8-K
- 5/8/24 - Form 424B7
- 5/8/24 - Form 10-Q
- EXAS's page on the SEC website